- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ITMN Market Currents
more »
-
April 27 Shares of InterMune (ITMN -14.5%) take a hit after posting a wider Q1 loss and missing on revenue estimates. Top line Esbriet sales came in short of reduced expectations, with just $4.9M in net sales.
Comment![Healthcare, On the Move, Earnings]
ITMN in Focus
more »
ITMN Related Articles
more »
ITMN News
more »
-
at MarketWatch.com (Tue, 6:40AM)
-
at MarketWatch.com (Mar 15, 2012)
-
at MarketWatch.com (Sep 13, 2011)
-
at MarketWatch.com (Sep 13, 2011)
-
at MarketWatch.com (Aug 18, 2011)
ITMN Press Releases and Filings
more »
-
PR Newswire (Mon, 4:50PM)
-
PR Newswire (Apr 26, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Apr 5, 2012)
-
PR Newswire (Mar 27, 2012)
ITMN Latest Transcript
more »
-
Tue, Nov 10, 2009
ITMN Cramer
more »
Currently, there are no Cramer articles on ITMN.
ITMN Instablog posts
more »
ITMN vs. ETF Alternatives
Company Description
We are a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. Hepatology is the field of medicine concerned with the diagnosis and... More
